Blood marker for protein misfolding outperforms P-tau 217 as early predictor of Alzheimer's disease
A study published in EMBO Molecular Medicine identifies amyloid beta protein misfolding as a highly effective blood-based predictor for Alzheimer's disease in asymptomatic stages. This marker outperforms the widely used P-tau 217 biomarker in early detection.
Why it matters
Improved early detection of Alzheimer's could significantly change clinical approaches to treatment and patient management before symptoms appear.
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00483-9 A study led by Professor Klaus Gerwert (PRODI, Ruhr University Bochum, Germany) has determined that the misfolding of the amyloid beta protein is the strongest blood-based predictor of Alzheimer's disease in the asymptomatic stage, indicating the risk of the disease years before it is clinically diagnosed and much earlier than the widely used plasma biomarker P-tau 217.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in